We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $113M
1-Year Est. Return 245.92%
This Fund
S&P 500
This Quarter Est. Return
+23.08%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$124M
AUM Growth
+$27.8M
Cap. Flow
+$31.4M
Cap. Flow %
25.36%
Top 10 Hldgs %
54.69%
Holding
32
New
14
Increased
7
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$7.03M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$5.65M
3
CTMX icon
CytomX Therapeutics
CTMX
+$4.57M
4
ALMS
Alumis Inc
ALMS
+$4.17M
5
URGN icon
UroGen Pharma
URGN
+$4.05M

Top Sells

Rank Stock Value
1
ATAI icon
AtaiBeckley Inc
ATAI
+$7.01M
2
IVA
Inventiva
IVA
+$4.6M
3
ABVX
Abivax
ABVX
+$4.29M
4
TSHA icon
Taysha Gene Therapies
TSHA
+$2.51M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$980K

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
2 Miscellaneous 18.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$9.63B
$10.6M 8.54%
32,810
+12,928
+65% +$4M
NERV icon
2
Minerva Neurosciences
NERV
$231M
$9.97M 8.06%
1,655,500
– –
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$6.7M 5.41%
200,000
+31,971
+19% +$1.25M
SLNO
4
PUT
DELISTED
Soleno Therapeutics
SLNO
$6.7M 5.41%
+200,000
New +$7.84M
OVID icon
5
Ovid Therapeutics
OVID
$547M
$6.26M 5.05%
2,818,459
+1,033,459
+58% +$1.85M
CMPS
6
Compass Pathways
CMPS
$1.9B
$5.78M 4.67%
+1,045,000
New +$7.03M
TARS icon
7
Tarsus Pharmaceuticals
TARS
$3.15B
$5.67M 4.58%
+80,859
New +$5.65M
SLDB icon
8
Solid Biosciences
SLDB
$1.05B
$5.52M 4.46%
766,974
+353,349
+85% +$2.27M
CMPX icon
9
CALL
Compass Therapeutics
CMPX
$432M
$5.29M 4.27%
+1,000,000
New +$5.77M
PMN icon
10
ProMIS Neurosciences
PMN
$124M
$5.26M 4.25%
414,219
+164,880
+66% +$2.46M
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.64B
$5.07M 4.1%
161,000
-34,000
-17% -$980K
QURE icon
12
CALL
uniQure
QURE
$3.38B
$4.91M 3.96%
300,000
+100,000
+50% +$2.02M
EPRX
13
Eupraxia Pharmaceuticals
EPRX
$441M
$4.78M 3.86%
660,375
+262,480
+66% +$2.11M
CTMX icon
14
CytomX Therapeutics
CTMX
$699M
$4.23M 3.42%
+900,000
New +$4.57M
IVA
15
Inventiva
IVA
$1.11B
$4.14M 3.34%
745,300
-754,700
-50% -$4.6M
CATX icon
16
Perspective Therapeutics
CATX
$355M
$3.86M 3.12%
+926,557
New +$3.91M
ABVX
17
Abivax
ABVX
$9.89B
$3.75M 3.03%
33,712
-36,288
-52% -$4.29M
ALMS
18
Alumis Inc
ALMS
$2.9B
$3.68M 2.97%
+166,959
New +$4.17M
URGN icon
19
UroGen Pharma
URGN
$2.13B
$3.63M 2.94%
+202,124
New +$4.05M
CAPR icon
20
Capricor Therapeutics
CAPR
$558M
$3.46M 2.8%
+113,899
New +$3.03M
MAZE
21
CALL
Maze Therapeutics
MAZE
$1.52B
$2.98M 2.41%
+100,000
New +$4.41M
WHWK
22
Whitehawk Therapeutics
WHWK
$263M
$2.82M 2.28%
817,939
– –
IKT icon
23
Inhibikase Therapeutics
IKT
$336M
$2.23M 1.8%
+1,325,000
New +$2.35M
REPL icon
24
CALL
Replimune Group
REPL
$1.46B
$1.89M 1.53%
246,900
-953,100
-79% -$7.29M
ANTX icon
25
AN2 Therapeutics
ANTX
$211M
$1.8M 1.45%
+526,315
New +$1.09M
1
2

Similar funds

IA
Invested Advisors State College, Pennsylvania $113M AUM 23.72% 1-Year Est. Return
CPA
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
MBC
Michael Brady & Co Westlake, Ohio $113M AUM
OCM
Objective Capital Management Pepper Pike, Ohio $113M AUM 22.81% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $113M AUM
TWS
Thomas W. Smith $113M AUM
OFP
OFC Financial Planning Short Hills, New Jersey $113M AUM 26.89% 1-Year Est. Return
IIM
IFC & Insurance Marketing Auburn, California $114M AUM

Ally Bridge Group's Q1 2026 Portfolio in Review

As of Q1 2026, Ally Bridge Group held 32 positions worth $124M, up 29% from $96M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Ally Bridge Group deployed $31.4M of net new capital in Q1 2026, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Compass Pathways: 1,045,000 shares worth $5.78M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Inventiva, an estimated $4.6M trimmed.

  • Ally Bridge Group's largest Q1 2026 buy was Compass Pathways: 1,045,000 shares worth $5.78M.
  • Ally Bridge Group added most to Praxis Precision Medicines in Q1 2026, an estimated $4M increase.
  • Ally Bridge Group's biggest Q1 2026 reduction was Inventiva, cutting an estimated $4.6M.
  • Ally Bridge Group fully exited AtaiBeckley Inc in Q1 2026, selling an estimated $7.01M.
  • Ally Bridge Group's ten largest holdings make up 55% of its $124M portfolio in Q1 2026.
  • Ally Bridge Group opened 14 new positions and closed 5 in Q1 2026.
  • Ally Bridge Group's portfolio value rose 29% quarter-over-quarter to $124M.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.